Compare Riot Platforms Inc (RIOT) vs 10X Genomics Inc (TXG) Price & Performance

RIOT stock trades at $16.84, down 9.17% in the past 24 hours amid bearish technical signals. The company shows concerning fundamentals with a net income margin of -196.28% and negative cash flow from operations of -$573 million in 2025. However, analyst sentiment remains overwhelmingly positive with 18 buy ratings and a consensus price target of $31.64, representing 88% upside potential. Recent strategic shifts toward AI data center operations with $9.8 billion in contracted lease revenue through 2048 provide long-term growth catalysts.

The outlook remains polarized between strong analyst optimism and challenging financial performance. Investment opportunity exists in RIOT's strategic pivot to AI infrastructure with secured long-term revenue streams, but substantial execution risks persist given current profitability challenges and negative cash flow generation. Stock investors face volatility from both Bitcoin price sensitivity and the company's transition to new business models.

10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.

The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.